MedTrace Logo

A Scintigraphy Study in Adults With Diabetic Gastroparesis

NCT04208698 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-08-10

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.

Conditions

  • Diabetic Gastroparesis

Interventions

DRUG

CIN-102 Dose 1

Deuterated domperidone (deudomperidone)

DRUG

CIN-102 Dose 2

Deuterated domperidone (deudomperidone)

DRUG

Placebo for CIN-102

Placebo

Sponsors & Collaborators

  • CinDome Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Brian Murphy, MD, MPH · CinRx Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-17
Primary Completion
2020-03-31
Completion
2020-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04208698 on ClinicalTrials.gov